These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22393169)

  • 1. Alterations in brain transition metals in Huntington disease: an evolving and intricate story.
    Rosas HD; Chen YI; Doros G; Salat DH; Chen NK; Kwong KK; Bush A; Fox J; Hersch SM
    Arch Neurol; 2012 Jul; 69(7):887-93. PubMed ID: 22393169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study.
    Domínguez JF; Ng AC; Poudel G; Stout JC; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
    J Neurol Neurosurg Psychiatry; 2016 May; 87(5):545-9. PubMed ID: 25952334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated brain iron is independent from atrophy in Huntington's Disease.
    Dumas EM; Versluis MJ; van den Bogaard SJ; van Osch MJ; Hart EP; van Roon-Mom WM; van Buchem MA; Webb AG; van der Grond J; Roos RA;
    Neuroimage; 2012 Jul; 61(3):558-64. PubMed ID: 22480728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol of IMAGINE-HD: Imaging iron accumulation and neuroinflammation with 7T-MRI + CSF in Huntington's disease.
    van de Zande NA; Bulk M; Najac C; van der Weerd L; de Bresser J; Lewerenz J; Ronen I; de Bot ST
    Neuroimage Clin; 2023; 39():103450. PubMed ID: 37327706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI measures of corpus callosum iron and myelin in early Huntington's disease.
    Di Paola M; Phillips OR; Sanchez-Castaneda C; Di Pardo A; Maglione V; Caltagirone C; Sabatini U; Squitieri F
    Hum Brain Mapp; 2014 Jul; 35(7):3143-51. PubMed ID: 24895252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.
    van Bergen JM; Hua J; Unschuld PG; Lim IA; Jones CK; Margolis RL; Ross CA; van Zijl PC; Li X
    AJNR Am J Neuroradiol; 2016 May; 37(5):789-96. PubMed ID: 26680466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative 7T phase imaging in premanifest Huntington disease.
    Apple AC; Possin KL; Satris G; Johnson E; Lupo JM; Jakary A; Wong K; Kelley DA; Kang GA; Sha SJ; Kramer JH; Geschwind MD; Nelson SJ; Hess CP
    AJNR Am J Neuroradiol; 2014 Sep; 35(9):1707-13. PubMed ID: 24742810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.
    Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.
    Bartzokis G; Tishler TA
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):821-33. PubMed ID: 10875443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications.
    Bartzokis G; Lu PH; Tishler TA; Fong SM; Oluwadara B; Finn JP; Huang D; Bordelon Y; Mintz J; Perlman S
    Neurochem Res; 2007 Oct; 32(10):1655-64. PubMed ID: 17484051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of iron imaging in Huntington's disease.
    van den Bogaard SJ; Dumas EM; Roos RA
    Int Rev Neurobiol; 2013; 110():241-50. PubMed ID: 24209441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical thickness, stance control, and arithmetic skill: An exploratory study in premanifest Huntington disease.
    Nanetti L; Contarino VE; Castaldo A; Sarro L; Bachoud-Levi AC; Giavazzi M; Frittoli S; Ciammola A; Rizzo E; Gellera C; Bruzzone MG; Taroni F; Grisoli M; Mariotti C
    Parkinsonism Relat Disord; 2018 Jun; 51():17-23. PubMed ID: 29496355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapping linked to function and structure in premanifest and symptomatic Huntington disease.
    Bechtel N; Scahill RI; Rosas HD; Acharya T; van den Bogaard SJ; Jauffret C; Say MJ; Sturrock A; Johnson H; Onorato CE; Salat DH; Durr A; Leavitt BR; Roos RA; Landwehrmeyer GB; Langbehn DR; Stout JC; Tabrizi SJ; Reilmann R
    Neurology; 2010 Dec; 75(24):2150-60. PubMed ID: 21068430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetization transfer imaging in premanifest and manifest huntington disease: a 2-year follow-up.
    van den Bogaard SJ; Dumas EM; Hart EP; Milles J; Reilmann R; Stout JC; Craufurd D; Gibbard CR; Tabrizi SJ; van Buchem MA; van der Grond J; Roos RA
    AJNR Am J Neuroradiol; 2013 Feb; 34(2):317-22. PubMed ID: 22918430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional subcortical shape analysis in premanifest Huntington's disease.
    Tang X; Ross CA; Johnson H; Paulsen JS; Younes L; Albin RL; Ratnanather JT; Miller MI
    Hum Brain Mapp; 2019 Apr; 40(5):1419-1433. PubMed ID: 30376191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased basal ganglia iron levels in Huntington disease.
    Bartzokis G; Cummings J; Perlman S; Hance DB; Mintz J
    Arch Neurol; 1999 May; 56(5):569-74. PubMed ID: 10328252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number.
    Gómez-Ansón B; Alegret M; Muñoz E; Monté GC; Alayrach E; Sánchez A; Boada M; Tolosa E
    Parkinsonism Relat Disord; 2009 Mar; 15(3):213-9. PubMed ID: 18632301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.